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Background: Liver hepatitis due to Hepatitis B (HBV) and hepatitis C virus (HCV) co-infection is the leading cause
of morbidity and mortality in HIV infected children and it is more severe in resource poor settings. Data on
seroprevalence of HBV and HCV among HIV infected children are scarce in Ethiopia. This study was conducted to
determine seroprevalence and risk factors of HBV and HCV and its effect on liver enzyme among HIV-positive children
aged 18 months to 15 years attending the paediatric HIV care and treatment clinic at Felege Hiwot referral hospital,
Ethiopia.
Methods: A cross-sectional study was conducted in May, 2014. Demographic and risk factors were collected using a
structured questionnaire. Hepatitis B surface antigen (HBsAg) and anti-HCV antibodies were detected using an enzyme
linked immunosorbent assay (ELISA). Alanine aminotransferase (ALT) levels were determined. The results were analyzed
using descriptive and logistic regression.
Results: A total of 253 HIV positive children, boys (52.5%) and girls (47.5%) took part in the study. The median age
of the children was 11 years. Overall, 19 (7.5%) of HIV infected children were positive either for HBsAg or anti-HCV
antibodies. The seroprevalence of HBV and HCV were 2.0% and 5.5%, respectively. All HBsAg positive children were
in older age groups (11-15years). Seroprevalence of HCV was higher in children from urban (7.7%) than rural (1.2%)
residents (P = 0.02). Overall, 29 (12.1%) of children had elevated ALT. Of these, 31.5% were from HBsAg or anti-HCV
antibody positive children whereas 9.8% were from hepatitis B or C virus negative children (P = 0.001). Multivariate
logistic regression showed that being positive for HBsAg or anti-HCV antibody (AOR: 4.7(95% CI: 1.5-13.5) was
significantly associated with elevated ALT.
Conclusion: HBV and HCV co-infections are common in HIV positive children. In HIV positive children, HBV and
HCV co-infection were associated with elevate ALT. Routine screening for HBV and HCV in HIV infected children
should be implemented.
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Co-infection of HIV positive population with hepatitis B
(HBV) and hepatitis C (HCV) is a global problem owing
to the shared routes of transmission. Prevention and
control of these infections are more challenging in sub-
Saharan Africa [1]. In Ethiopia, 1.3 million people live
with HIV (78% adults and 22% children < 14 years) [2].* Correspondence: bayeabera15@gmail.com
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unless otherwise stated.Although, the exact prevalence of HIV in children in
Ethiopia is not known, approximately, 154,084 children
live with HIV in 2014 and 16,000 children were receiv-
ing ART in 2013 [2].
Globally, over 350 and 170 million people are chronic-
ally infected with HBV and HCV, respectively [3,4]. In
sub-Saharan Africa, the overall prevalence of HBV and
HCV co- infection in HIV infected people were 15% and
7%, respectively [5]. In Ethiopia, virtually, all data on
sero-prevalence of HBV and HCV have been docu-
mented from adults [6,7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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liver infection with potential to liver cirrhosis and hepato-
cellular carcinoma [8]. Studies showed that HBV and
HCV infections are the major causes of morbidity and
mortality in HIV positive population related to liver
cirrhosis and hepatocelular carcinoma [9,10]. The risk
for development of liver cirrhosis is twice in HCV/HIV
co-infected than HIV mono infected groups [11]. A
study conducted in Thailand showed that HBV and
HCV co-infection accounted for increased mortality in
ART-naïve patients [12].
WHO recommends screening for HBV and HCV be-
fore initiating ART [13]. However, in Ethiopia screening
for HBV and HCV in HIV positive individuals is not
practiced. For instance, a recent study in the same area
reported 6.6% HIV prevalence and 19.0% HBV-HIVco-
infection in pregnant women, respectively [14]. There is
a paucity of seroprevalence data on HBV and HCV in
HIV infected children in Ethiopia. This study was there-
fore undertaken to determine seroprevalence and risk
factors of HBVand HCV and its effect on liver ALT
among HIV infected children aged 18 months to 15 years
at Felege Hiwot referral hospital, Ethiopia.
Methods
Study design and setting
A hospital based cross-sectional study was conducted
among HIV infected children at Felege hiwot referral
hospital in May 2014. The hospital is one of the
government-sponsored ART centers in Bahir Dar city.
This hospital provides chronic HIV care (both pre-ART
and ART) services. At the time of study, there were 1,
810 HIV positive children (810 Pre-ART and 1000 on
ART) HIV at Felege hiwot pediatric ART clinic [per-
sonal communication]. The choice of ART was based
on the Ethiopian ART guidelines. The three first line
regimens generally comprised of [Tenofovir (TDF) +
Lamivudine (3TC) + Nevirapine (NVP)/Efavirenz (EFV);
or Zidovudine (AZT) +3TC + NVP/EFV; or Stavudine
(d4T) +3TC + NVP/EFV] [15].
Sample size and sampling technique
Sample size was determined using Epi info version 7.0
(public domain soft ware www.cdc.gov) considering 95%
confidence level, marginal error of (5%) and 10%
prevalence of HBsAg [1]. Thus, sample size of 239
was calculated and10% (n = 24) was added for non-
respondents. Random sampling technique was used to
enroll the study participants using their registration
logbook.
Sample collection and processing
A pre-tested questionnaire was used to collect data on
demographic characteristics and associated risk factorssuch as sex, age, duration of ART, history blood transfu-
sion, female genital mutilation (FGM), uvulectomy and
residence of by face to face interviewing the childrens’
parent. The presence of hepatitis B surface antigens
(HBsAg) and anti-HCV antibody (IgG and IgM) were
detected on sera using ELISA according to the manufac-
turer’s instruction (Linear Chemicals. Joaquim Costa,
Barcelona, Spain). The catalytic activity of ALT (alanine
amino transferase) was determined in serum using
Beckman Coulter Synchron Clinical Systems auto lab
analyzer (Beckman Coulter Inc. Fullerton, USA). Normal
value for ALT at 37°C (0–40 IU/L) was taken for both
females and males. Laboratory quality controls were
maintained by following standardized procedures dur-
ing blood sample collection, storage and analytical
process. Internal positive and negative controls were
run alongside of the test.
Statistical analysis
Data was analyzed using the Statistical Package for Social
Sciences (SPSS® 20, USA). All explanatory variables with a
p value ≤0.2 in the bivariate analysis were included in the
multivariate logistic regression model to identify inde-
pendent predictive variables. Odds ratio (OR) and 95%
confidence intervals (CI) were calculated and the result
was considered statistically significant at p < 0.05. Fisher’s
exact test was used to test categorical variables.
Ethical consideration
The study was ethically approved by the Research and
Ethical Review Board of Bahir Dar University. Moreover,
all parents of children gave written consent to partici-
pate in this study. Children positive for HBSAg and ant-
HCV antibody were reported to ART clinic pediatrician
for further investigation and follow-up.
Operational definition of liver toxicity degree according
to WHO
Degree 0: the level of toxicity considered normal when
its value is >1.25 × normal value of ALT.
Degree 1: the level of toxicity considered as weak when
its value is 1.256 – 2.5 × normal value of ALT.
Degree 2: the level of toxicity considered as moderate
when its value is 2.6 – 5 × normal value of ALT.
Degree 3: the level of toxicity considered as severe
when its value is 5.1 – 10 × normal value of ALT.
Degree 4: the level of toxicity considered as severe
when its value is >10 × normal value of ALT.
Results
Demographic characteristics
A total of 253 HIV infected children participated in the
present study. Among these, 133 (52.5%) were boys and
120 (47.5%) were girls. The median age of the children
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The median length of time on ART was 48 months. During
the study period, 96.7% of children were on the first line
ART regimen. Demographic characteristics of hepatitis
co-infection in children are summarized in Table 1.
Seroprevalence of hepatitis B and C viruses
Overall, 19 (7.5%) HIV infected children were positive
either for HBsAg or ant-HCV antibodies. The seropreva-
lence of HCV and HBV were 5.5% and 1.2%, respect-
ively. No study participant was positive for both HBV
and HCV. All HBsAg positive children were in older age
groups between 11–15 years of age (Table 1). Hepatitis
co-infected children were significantly older than their
HIV-mono infected counter parts (P = 0.01) (Table 2).
The seroprevalence of HCV was higher in children from
urban than rural residents (P = 0.02). However, statistical
significance difference was not observed between HBV
prevalence and age groups. The results of the investi-
gated potential risk factors are depicted in Table 2.
Overall, significant association was not observed for
seroprevalence of hepatitis and any of the investigated
risk factors (Table 2).
Associated risk factors
According to WHO classification of HIV stage, 31.6% of
children were either in stage 3 or 4 HIV (Table 2). In this
study, 25 (20.8%) of the girls had female genital mutilation
(FGM) and 53 (21%) had traditional uvulectomy. Nine par-
ticipants (3.5%) had history of blood transfusion. Among
those with history of uvulectomy, 9.4% of them were posi-
tive for anti-HCV antibody. Among blood transfusion re-
cipients, 1/9 (1.1%) was positive for anti-HCV antibody.
Conversely, none of them were positive for HBsAg.
Alanine amino transferase (ALT)
Among 222 children on ART, 29 (12.1%) had elevated
ALT compared to 2 (6.4%) among 31 on pre-ART groupsTable 1 Seroprevalence of HBV and HCV and demographic ch
Ethiopia, 2014










Total 253(Table 3). The proportion of elevated ALT among HBsAg
or anti-HCV antibody positive children was 31.5%. But,
9.8% elevated ALT was from those without hepatitis
co-infection. Nineteen (7.5%) of participants had grade 1
and 2 liver toxicity. Of these, only three children (1.2%)
developed grade 2 liver toxicity. However, none of the
study participants developed either grade 3 or 4 liver
toxicity. Multivariate logistic regression analysis showed
that being positive for HBsAg or anti-HCV antibody
(AOR: 4.7(95%CI: 1.5-13.5) was significantly associated
with elevated ALT (Table 3).
Discussion
The present study demonstrated the prevailing sero-
prevalence of HBV and HCV in HIV infected children
for the first time in Ethiopia. The antiretroviral therapy
(ART) program in Ethiopia has significantly reduced
morbidity and mortality in HIV infected individuals [16].
However, liver diseases from HBV and HCV co-infection
may have negative impact on the success of ART
program particularly in resource poor settings where
facilities are limited for HBV and HCV testing and
monitoring.
The HBsAg prevalence in HIV infected children in this
study (2.0%) is comparable with studies in Thailand
(3.3%), Democratic Republic of Congo (1.6%) and
Tanzania (1.2%) and [12,17,18]. In contrast, it is lower
compared to other studies in Africa. For instance, 5.8%
to 15.9% of HBV/HIV sereoprevalence in HIV infected
children was reported in West Africa [19-22]. Moreover,
it is far lower than the HBsAg prevalence (11.2% to
19.0%) among HIV positive adults in the same study
area in Bahir Dar [14,23]. To our knowledge, there are
no data on HBsAg in HIV positive children in Ethiopia
therefore we could not compare our results directly with
similar age groups.
This low HBsAg prevalence in children cannot be







2 (1.7) 4 (3.3) 6 (5.0)
3 (2.2) 10 (7.5) 13 (9.7)
5 (2.0) 14 (5.5) 19 (7.5)
0 (0) 1 (7.1) 1 (7.1)
0 (0) 4 (3.9) 4 (3.9)
5 (3.6) 9 (6.6) 14 (10.2)
5 (2.0) 14 (5.5) 19 (7.5)
Table 2 Association of local risk factors for HBV and HCV co-infection in HIV infected children, North West, Ethiopia,
2014
Variables Total sample HBSAg positive N (%) P value HCV seropositive N (%) P value
Sex
Girls 120 2 (1.7) 0.56 4 (3.3) 0.14
Boys 133 3 (2.2) 10 (7.5)
Mean age (years) 11.1 ± 3.4** 13.4 ± 2.7 0.001 12.5 ± 4.1 0.01
Residence
Urban 169 2 (1.2) 0.16 13 (7.7) 0.02
Rural 84 3 (3.5) 1 (1.2)
Uvulectomy
Yes 53 0 (0) NA 5 (9.4) 0.16
No 200 5 (2.5) 9 (4.3)
Blood transfusion
Yes 9 0 (0) NA 1 (1.1) NA
No 244 5 (2.0) 13 (5.3)
FGM
Yes 25 0 (0) NA 1 (4.0) NA
No 228 5 (2.2) 13 (5.7)
WHO staging
1 and 2 173 4 0.41 9 0.46
3 and 4 80 1 5
**: Mean age for mono HIV infection; NA: not applicable, FGM: female genital mutilation.








Female (n = 120) 10 (9.0) 0.5 (0.22-1.30) 0.36 (0.03-2.7)
male (n = 133) 19 (14.3)
ART status
On ART (n = 222) 27 (12.2) 1.6 (0.35-7.3) 2.0 (0.43-6.8)
Not on ART (n = 31) 2 (6.4) 1.0
Residence
Urban (n = 169) 16 (9.4) 1.0
Rural (n = 84) 13 (15.4) 0.51 (0.22-1.2) 3.2 (1.2-8.2)*
HBSAg
Positive (n = 5) 3 (60) 1.9 (0.22-18.1) 0.49 (0.06-4.3)
Negative (n = 248) 26 (10.5) 1.0
Anti-HCV Ab
Positive (n = 14) 3 (21.4) 2.3 (0.4-10.0) 1.6 (0.22-11.5)
Negative (n = 239) 26 (5.8) 1.0
Anti-HCV or HBsAg
Positive (n = 19) 6 3.2 (1.4-14.2) 4.7 (1.5-13.5)**
Negative (n = 234) 23 1.0
*: P value 0.01 and **P value = 0.001; ART: antiretroviral therapy; AOR: adjusted odds ratio; COR: crud odds ratio; anti-hepatitis C virus antibodies; CI: confidence interval.
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factors may be occult hepatitis B virus infection (OBI)
because OBI is common in HIV infected children [24].
Furthermore, the effect of the potential anti-hepatitis B
virus agent lamivudine (3TC) may be attributed to low
prevalence in HBV. Because, 87.7% of HIV infected
participants were on ART that contain 3TC [15]. The
investigated local risk factors such as female genital mu-
tilation (FGM), uvuloctomy, blood transfusion and
WHO HIV staging had no significant association with
prevalence of HBsAg. The only associated risk factor for
HBsAg positive was age of the participants (P = 0.001)
(Table 2). Likewise, studies in a Nigeria and USA
reported that HBV co-infection was associated in chil-
dren aged 11–15 years [20,25].
The seroprevalence of HCV in this study (5.5%)
conforms to the estimated prevalence of HCV in Africa
(5.3%), which is the highest in the world [26]. It is also
comparable with reports from Nigeria (6.8%) [27].
Comparison was not possible in Ethiopian context
owing to lack of HCV seroprevalence data in HIV
infected children. Although, the study population is
different, previous studies in Ethiopia reported 4.5 to
9.2% HCV seroprevalence in HIV positive adults
[28,29]. In contrast, in other studies 13.5% and 10.3%
seroprevalence of HCV were reported in HIV-infected
children [16,30].
In this study, local risk factors for hepatitis co-infection
were investigated hence 20.8% of girls had female genital
mutilation (FGM). This is similar with the national data
which stated that 25% of 0–14 years old children had
FGM [31]. But, in our study none of them were found
to be positive for either of the hepatitis virus markers.
Although, statistical significant association was not
noted, children who have had history of traditional
uvulecyomy had higher HCV seroprevalnce (9.4%) than
their counterparts without history of uvulecyomy
(4.3%). In this study, seroprevalence of HCV was higher
in children from urban (7.7%) than rural children (1.2%)
(P = 0.02). The other investigated potential risk factors
were not significantly associated with seroprevalence of
HCV or HBV (Table 2).
Regards to ALT, liver toxicity was mild since none of
the participants developed either grade 3 or 4 liver
toxicity. However, 7.5% of children developed grade 1
and 2 of liver toxicity. ART usage had no significant
association with elevated ALT. Similarly, in Tanzanian
children no association was documented between usage
of ART and elevated ALT [18]. This may be elucidated
by duration of ART and in this study 96.7% of children
were on the first line ART regimen during the study
period. Using multivariate logistic regression analysis,
children positive either for HBsAg or anti-HCV antibody
had 4.7 times more risk of elevated ALT (Table 3).This study was not without limitation thus detecting
of active replication of HCV and its genotype in anti-
HCV patients may be more accurate than antibody test
but were not possible due to the limitations of working
in resource poor settings [32]. However, these data
showing a high rate of HCV co-infection highlight the
urgent need for more detailed characterization HCV by
HCV RNA testing and HCV genotyping. Thus, prelimin-
ary information on HCV has paramount importance to
plan resources to avail the emerging curative treatment
for HCV using direct acting antiviral agents (DAAs) that
are associated with high (>95%) cure rates.
Conclusion
Overall seroprevalence of hepatitis B and C viruses in
HIV positive children were high. Hepatitis co-infections
in HIV positive children were associated with elevated
ALT. Therefore, routine screenings for HBV and HCV
in HIV positive children need to be in place.
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